Treatment as prevention: Preparing the way

Journal of the International AIDS Society

Volumn 14, Issue SUPPL. 1, 2011, Pages

  Williams, Brian ^a   Wood, Robin ^b   Dukay, Victor ^c   Delva, Wim ^a,d   Ginsburg, David ^e   Hargrove, John ^a   Stander, Martinus ^f   Sheneberger, Robert ^g   Montaner, Julio ^h   Welte, Alex ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Lundy Foundation   (United States)

^d GHENT UNIVERSITY   (Belgium)

^e Rural Development Consultant   (South Africa)

^f Health Econometrix and Outcomes Research (HeXor)   (South Africa)

^g UNIVERSITY OF MARYLAND   (United States)

^h BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; DISEASE TRANSMISSION; EMPOWERMENT; EPIDEMIC; HEALTH CARE POLICY; HETEROSEXUALITY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICAL INFORMATION; PATIENT MONITORING; PREVENTION STUDY; PRIORITY JOURNAL; REVIEW; ARTICLE; PREVENTIVE MEDICINE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; PREVENTIVE MEDICINE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79960105304     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-14-S1-S6     Document Type: Review

References (55)

1. UNAIDS Report on the Global AIDS Epidemic. UNAIDS, 2010 http://www.unaids.org/documents/20101123-GlobalReport-em.pdf
2. Untangling the Web of Antiretroviral Price Reductions. MSF Campaign for Access to Essential Medicines, http://utw.msfaccess.org/background/aids- progress-under-siege
3. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. RM Granich CF Gilks C Dye KM De Cock BG Williams, Lancet 2009 373 48 57 10.1016/S0140-6736(08)61697-9 19038438
4. Cost-efectiveness of highly active antiretroviral therapy in South Africa. M Badri G Maartens S Mandalia LG Bekker JR Penrod RW Platt R Wood EJ Beck, PLoS Med 2006 3 4 10.1371/journal.pmed.0030004 16318413
5. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. WHO, Progress report 2009 http://www.who.int/hiv/pub/ 2009progressreport/en/
6. Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. MJ McElrath, J Infect Dis 2010 202 Suppl 2 323 326 20846040
7. The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. S Berkley K Bertram J-F Delfraissy R Draghia-Akli A Fauci C Hallenbeck J Kagame P Kim D Mafubelu MW Makgoba P Piot M Walport M Warren T Yamada J Esparza C Hankins MI Johnston Y Lévy M Manuel Romaris R Ahmed A Bernstein, Nat Med 2010 16 981 989 10.1038/nm0910-981 20823883
8. HIV-1 vaccine development after STEP. DH Barouch B Korber, Annu Rev Med 2010 61 153 167 10.1146/annurev.med.042508.093728 20059334
9. Biological and behavioural impact of an adolescent sexual health intervention in Tanzania: a community-randomized trial. DA Ross J Changalucha AI Obasi J Todd ML Plummer B Cleophas-Mazige A Anemona D Everett HA Weiss DC Mabey H Grosskurth RJ Hayes, AIDS 2007 21 1943 1955 10.1097/QAD.0b013e3282ed3cf5 17721102 (Pubitemid 47329771)
10. Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review. SI McCoy RA Kangwende NS Padian, AIDS Behav 2010 14 469 482 10.1007/s10461-009-9644-9 19949847
11. Treating curable sexually transmitted infections to prevent HIV in Africa: still an effective control strategy? RG White KK Orroth JR Glynn EE Freeman R Bakker JD Habbema F Terris-Prestholt L Kumaranayake A Buve RJ Hayes, J Acquir Immune Defic Syndr 2008 47 346 353 10.1097/QAI.0b013e318160d56a 18176323 (Pubitemid 351619422)
12. A model for the roll-out of comprehensive adult male circumcision services in African low-income settings of high HIV incidence: the ANRS 12126 Bophelo Pele Project. P Lissouba D Taljaard D Rech S Doyle D Shabangu C Nhlapo J Otchere-Darko T Mashigo C Matson D Lewis S Billy B Auvert, PLoS Med 2010 7 1000309 10.1371/journal.pmed.1000309 20652013
13. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial. B Auvert D Taljaard E Lagarde J Sobngwi-Tambekou R Sitta A Puren, PLoS Med 2005 2 298 10.1371/journal.pmed.0020298 16231970
14. HIV transmission rates in Thailand: evidence of HIV prevention and transmission decline. LS Park T Siraprapasiri W Peerapatanapokin J Manne L Niccolai C Kunanusont, J Acquir Immune Defic Syndr 2010 54 430 436 20418773
15. Condoms and prevention of HIV. AM Foss CH Watts P Vickerman L Heise, Br Med J 2004 329 185 186 10.1136/bmj.329.7459.185 (Pubitemid 39013273)
16. Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials. SS Abdool Karim, Future Microbiology 2010 5 527 529 10.2217/fmb.10.29 20353292
17. Anti-retroviral therapy for the control of HIV-associated tuberculosis: modelling the potential effects in nine African countries. BG Williams R Granich K De Cock P Glaziou A Sharma C Dye, Proc Natl Acad Sci USA 2010 107 17853 17854
18. The epidemiological impact of Tenofovir gel on HIV in South Africa. BG Williams S Abdool Karim E Gouws Q Abdool Karim, XVIII International AIDS Conference; July 18-23 2010; Vienna, Austria 21589951
19. Preexposure chemoprophylaxis for hiv prevention in men who have sex with men. RM Grant JR Lama PL Anderson V McMahan AY Liu L Vargas P Goicochea M Casapia JV Guanira-Carranza ME Ramirez-Cardich O Montoya-Herrera T Fernandez VG Veloso SP Buchbinder S Chariyalertsak M Schechter L-G Bekker KH Mayer EG Kallas KR Amico K Mulligan LR Bushman RJ Hance C Ganoza P Defechereux B Postle F Wang JJ McConnell J-H Zheng J Lee JF Rooney HS Jaffe Al Martinez DN Burns DV Glidden, N Engl J Med 2010 363 2587 2599 10.1056/NEJMoa1011205 21091279
20. HIV-1 dynamics in vivo: implications for therapy. V Simon DD Ho, Nat Rev Microbiol 2003 1 181 190 10.1038/nrmicro772 15035022
21. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. S Palmer F Maldarelli A Wiegand B Bernstein GJ Hanna SC Brun DJ Kempf JW Mellors JM Coffin MS King, Proc Natl Acad Sci USA 2008 105 3879 3884 10.1073/pnas.0800050105 18332425 (Pubitemid 351723493)
22. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. S Attia M Egger M Muller M Zwahlen N Low, AIDS 2009 23 1397 1404 10.1097/QAD.0b013e32832b7dca 19381076
23. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. D Donnell JM Baeten J Kiarie KK Thomas W Stevens CR Cohen J Mclntyre JR Lingappa C Celum, Lancet 2010 375 2092 2098 10.1016/S0140-6736(10)60705-2 20537376
24. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. JR Lingappa JP Hughes RS Wang JM Baeten C Celum GE Gray WS Stevens D Donnell MS Campbell C Farquhar M Essex Jl Mullins RW Coombs H Rees L Corey A Wald, PLoS ONE 2010 5 12598 10.1371/journal.pone.0012598 20856886
25. Modelling the impact of ART on the epidemic of HIV. BG Williams V Lima E Gouws, Curr HIV Res 2011
26. Evaluating the risk of HIV transmission through unprotected orogenital sex. J del Romero B Marincovich J Castilla S Garcia J Campo V Hernando C Rodriguez, AIDS 2002 16 1296 1297 10.1097/00002030-200206140-00017 12045500 (Pubitemid 34666669)
27. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. O Keiser C Orrell M Egger R Wood MW Brinkhof H Furrer G van Cutsem B Ledergerber A Boulle, PLoS Med 2008 5 148 10.1371/journal.pmed.0050148 18613745
28. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. NS Padian A Buve J Balkus D Serwadda W Cates Jr., Lancet 2008 372 585 599 10.1016/S0140-6736(08)60885-5 18687456
29. Combination HIV Prevention: Significance, Challenges, and Opportunities. AE Kurth C Celum JM Baeten SH Vermund JN Wasserheit, Current HIV/AIDS Reports 2011 8 62 72 10.1007/s11904-010-0063-3 20941553
30. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. JS Montaner R Hogg E Wood T Kerr M Tyndall AR Levy PR Harrigan, Lancet 2006 368 531 536 10.1016/S0140-6736(06)69162-9 16890841 (Pubitemid 44142776)
31. Highly active antiretroviral treatment for the prevention of HIV transmission. R Granich S Crowley M Vitoria YR Lo Y Souteyrand C Dye C Gilks T Guerma KM De Cock B Williams, Journal of the International AIDS Society 2010 13 1 10.1186/1758-2652-13-1 20205768
32. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. R Granich S Crowley M Vitoria C Smyth JG Kahn R Bennett YR Lo Y Souteyrand B Williams, Current Opinion in HIV AIDS 2010 5 298 304 10.1097/COH.0b013e32833a6c32
33. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. RP Walensky AD Paltiel E Losina BL Morris CA Scott ER Rhode GR Seage KA Freedberg, Clin Infect Dis 2010 51 392 400 10.1086/655130 20617921
34. Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy? BG Wagner JS Kahn S Blower, AIDS 2010 24 775 776 10.1097/QAD. 0b013e3283366782 20177359
35. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. RJ Smith JT Okano JS Kahn EN Bodine S Blower, Science 2010 327 697 701 10.1126/science.1180556 20075214
36. Treating our way out of the HIV pandemic: could we, would we, should we? GR Garnett RF Baggaley, Lancet 2009 373 9 11 10.1016/S0140-6736(08)61698-0 19038439
37. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. PJ Dodd GR Garnett TB Hallett, AIDS 2010 24 729 735 10.1097/QAD.0b013e32833433fe 20154580
38. An age-structured model for the potential impact of generalized access to antiretrovirals on the South African HIV epidemic. N Bacaer C Pretorius B Auvert, Bull Math Biol 2010 72 2180 2198 10.1007/s11538-010-9535-2 20349152
39. A community trial of the impact of improved sexually transmitted disease treatment on the HIV epidemic in rural Tanzania: 1. Design. R Hayes F Mosha A Nicoll H Grosskurth J Newell J Todd J Killewo J Rugemalila D Mabey, AIDS 1995 9 919 926 10.1097/00002030-199508000-00014 7576328
40. HIV prevention research: taking stock and the way forward. R Hayes S Kapiga N Padian S McCormack J Wasserheit, AIDS 2010 24 SuppI 4 81 92 21042056
41. Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda. LW Chang S Alamo S Guma J Christopher T Suntoke R Omasete JP Montis TC Quinn M Juncker SJ Reynolds, J Acquir Immune Defic Syndr 2009 50 276 282 10.1097/QAI.0b013e3181988375 19194316
42. HIV & AIDS in Botswana. AVERT, http://www.avert.org/aids-botswana.htm
43. HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. BG Williams EL Korenromp E Gouws GP Schmid B Auvert C Dye, J Infect Dis 2006 194 1450 1458 10.1086/508206 17054076 (Pubitemid 44706515)
44. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. JW Mellors CR Rinaldo Jr. P Gupta RM White JA Todd LA Kingsley, Science 1996 272 1167 1170 10.1126/science.272.5265.1167 8638160 (Pubitemid 26001148)
45. Consultation on Antiretroviral Treatment for Prevention of HIV Transmission. WHO, Meeting Report. 2-4 November 2009; Geneva 2010 19746560
46. Test-and-Treat Strategy for HIV in Resource-Limited Settings. S Lockman, Medscape 2010 http://www.medscape.com/viewarticle/727536
47. A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States. TLC-Plus, http://www.hptn.org/webdocuments/HPTN065/HPTN065ProtocolFINALVer1-01Mar10.pdf
48. PopART- Population effects of Anti Retroviral Therapy. Department of Medicine, Imperial College, London http://www1.imperial.ac.uk/ departmentofmedicine/divisions/infectiousdiseases/infectious-diseases/ hiv-trials/popart/
49. Test-and-Treat Strategy to End AIDS. Test and Treat to End AIDS, http://www.ttea.info
50. Traiter toutes les personnes infectées par le VIH: un impact sur la pandémie? ANRS, http://www.groupesida.ch/filrouge/archives/2010/11/ anrs-traiter-toutes-les-person/
51. Ending New HIV Infections in Swaziland: A Catalytic Model for Southern Africa. Stop AIDS Now! http://www.stopaidsnow.org/
52. Unprecedented effort to seek, test, and treat inmates with HIV: NIH research to improve public health with focus on prison and jail systems across the United States. NIH, 2010 http://www.nih.gov/news/health/sep2010/nida-23.htm
53. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. WHO, Progress report 2008 http://www.who.int/hiv/pub/ 2008progressreport/en/index.html
54. When to Start Therapy: Chronic HIV Infection. JE Gallant, Johns Hopkins HIV Guide http://www.hopkins-aids.edu/management/antiretroviral-therapy/when-to- start-therapy.html?contentlnstanceld=7666
55. Universal Antiretroviral Therapy Initiation: Guideline of the HIV/AIDS Division at San Francisco General Hospital. Updated January 31 2010